The purpose of this study is to evaluate the safety and efficacy of a single injection of CNTX-4975 in subjects with chronic, moderate to severe osteoarthritis knee pain.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
175
Achieve Clinical Research, LLC
Birmingham, Alabama, United States
Change from Baseline through Week 12 in average knee index pain with walking over previous 24 hours using WOMAC A1 question in subjects treated with CNTX-4975 1.0 mg compared to placebo in subjects with osteoarthritis (OA) of the knee
Time frame: At 12 Weeks
Change from Baseline through Week 12 in average index knee pain with walking using WOMAC A1 question in subjects treated with CNTX 0.5 mg compared to placebo
Time frame: At 12 Weeks
Change from Baseline to each study visit through Week 24 in average index knee pain with walking using WOMAC A1 in subjects treated with CNTX-4975 compared to placebo
Time frame: Up to 24 weeks
Change from Baseline through Week 4 in the average index knee pain with walking using the WOMAC A1 question
Time frame: Up to 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Advanced Arizona Clinical Research
Tucson, Arizona, United States
Dream Team Clinical Research, LLC
Anaheim, California, United States
Hope Clinical Research, LLC
Canoga Park, California, United States
TriWest Research Associates
El Cajon, California, United States
BioSolutions Clinical Research Center
La Mesa, California, United States
Axis Clinical Trials
Los Angeles, California, United States
Avail Clinical Research, LLC
DeLand, Florida, United States
Finlay Research Clinic
Hialeah, Florida, United States
Eastern Research
Hialeah, Florida, United States
...and 12 more locations